hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-02. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
14,810, 17 March 2008 - The SENSEX dropped by 951.03 points on the global credit crisis and distress, to fall below the 15,000 mark, closing at 14,810. The month ended with the SENSEX shedding 726.85 points on 31 March 2008, after heavy selling in blue-chip stocks on global economic fears.
== Metalloenzymes == Metalloenzymes all have one feature in common, namely that the metal ion is bound to the protein with one labile coordination site. As with all enzymes, the shape of the active site is crucial. The metal ion is usually located in a pocket whose shape fits the substrate. The metal ion catalyzes reactions that are difficult to achieve in organic chemistry. These metalloenzymes acts in accordance to radical chemistry as these metalloenzymes use various techniques to create, stabilize, and use highly reactive radical intermediates.
==== Other leads ==== For Samuil Aronovich Kaplan, "the most reliable criterion" remains the small angular diameter of the radio source. The wavelength of 21 cm, privileged since 1959, according to the study of Cocconi and Morrison, is not the only listening region. Kaplan, in 1971, also mentioned the radio region of the spectrum, characterized by the hydroxyl radical (OH). For Livio, the means of detection should focus on globular clusters, the regions most likely to harbor planets similar to the Earth. For Guillermo A. Lemarchand, extraterrestrial civilizations should not use an omnidirectional transmitter. Instead, they should look for signals of weak information, intermittent and unidirectional. They will certainly need to use interferometry to inspect planetary systems where life might appear. From Earth, it would be possible to pick up such signals at distances of up to 35 + (t_f - 2000) / 2, where t_f is the observation date in years, knowing that t_f ≥ 2000. However, there are many techniques for transmitting an interstellar message, ranging from bosons to particles and even antiparticles. An artificial source located in the accretion disk of a supermassive black hole would be undetectable by the beams used to transmit the collected energy. In fact, the probability of detecting a beam of one micron arc-second is less than 10−23. Moreover, the energy emitted by the black hole would not allow detection of the energy used by the Type III civilization.
== Terminology == The term rheumatism stems from the Late Latin rheumatismus, ultimately from Greek ῥευματίζομαι "to suffer from a flux", with rheum meaning bodily fluids, i.e., any discharge of blood or bodily fluid. Before the 17th century, the joint pain which was thought to be caused by viscous humours seeping into the joints was always referred to as gout, a word adopted in Middle English from Old French gote "a drop; the gout, rheumatism". The English term rheumatism in the current sense has been in use since the late 17th century, as it was believed that chronic joint pain was caused by excessive flow of rheum which means bodily fluids into a joint.
The penultimate process is called conching. A conche is a container filled with metal beads, which act as grinders. The refined and blended chocolate mass is kept in a liquid state by frictional heat. Before conching, chocolate has an uneven and gritty texture. The conching process produces cocoa and sugar particles smaller than the tongue can detect (typically around 20 μm) and reduces rough edges, hence the smooth feel in the mouth. The length of the conching process determines the final smoothness and quality of the chocolate. After the process is complete, the chocolate mass is stored in tanks heated to about 45–50 °C (113–122 °F) until final processing. After conching, chocolate is tempered to crystallize a small amount of cocoa butter. Cocoa butter is a polymorphic fat with six different crystal forms, but only one of them—Form V—gives chocolate its characteristic snap, gloss, and stable texture. Tempering eliminates the undesirable crystal forms and promotes the formation of Form V. After chocolate has been tempered, it is molded into different shapes, including chocolate bars and chocolate chips.
Sources: en.wikipedia.org
By the 1820s, the different Nonconformists, including Wesleyan Methodists, Baptists, Congregationalists and Unitarians, had formed the Committee of Dissenting Deputies and agitated for repeal of the highly restrictive Test and Corporation Acts. These Acts excluded Nonconformists from holding civil or military office or attending Oxford or Cambridge, compelling them to set up their own Dissenting Academies privately. The Tories tended to be in favour of these Acts and so the Nonconformist cause was linked closely to the Whigs, who advocated civil and religious liberty. After the Test and Corporation Acts were repealed in 1828, all the Nonconformists elected to Parliament were Liberals. Nonconformists were angered by the Education Act 1902, which integrated Church of England denominational schools into the state system and provided for their support from taxes. John Clifford formed the National Passive Resistance Committee and by 1906 over 170 Nonconformists had gone to prison for refusing to pay school taxes. They included 60 Primitive Methodists, 48 Baptists, 40 Congregationalists and 15 Wesleyan Methodists. The political strength of Dissent faded sharply after 1920 with the secularisation of British society in the 20th century. The rise of the Labour Party reduced the Liberal Party strongholds into the nonconformist and remote "Celtic Fringe", where the party survived by an emphasis on localism and historic religious identity, thereby neutralising much of the class pressure on behalf of the Labour movement.
Erastin is a small molecule capable of initiating ferroptotic cell death. Erastin binds and activates voltage-dependent anion channels (VDAC) by reversing tubulin's inhibition on VDAC2 and VDAC3, and functionally inhibits the cystine-glutamate antiporter enzyme SLC7A11 Cells treated with erastin are deprived of cysteine and are unable to synthesize the antioxidant glutathione. Depletion of glutathione eventually leads to excessive lipid peroxidation and cell death. Erastin was first described in 2003. Its name is short for "eradicator of RAS and ST-expressing cells".
=== Types of microneedle === There are many types of microneedle that are distinguished by the shape and other characteristics. The types include: Dissolvable MNPs, solid non-soluble MNPs, and hollow MNPs. Different MNPs may be chosen depending on the situation and the drug properties.
=== US 1938–1947 === Eltenton was an open admirer of the USSR and its people. Both he and his wife gave lectures at the California Labor School on Russian life, and were active in the American Russian Institute. He was also a trade union activist for the Federation of Architects, Engineers, Chemists and Technicians at Shell, and was at a meeting where Robert Oppenheimer encouraged the formation of a section at the Lawrence Berkeley National Laboratory. In 1939, with the beginning of the Second World War he contacted the British Embassy to volunteer, but was told his work for the oil company was better use of his talents. In 1941 the USSR was invaded by Germany, and he and his wife became active members of the Russian War Relief organization. In May 1942, after the US had also joined the war and was therefore an ally of the USSR, the Eltentons had Piotr Ivanov, the vice consul of the Soviet consulate in San Francisco as a dinner guest. It was there that Ivanov raised the possibility of atomic research being shared between the US and the USSR, and suggested three scientists who might be prepared to do so, if discretion could be assured. Eltenton was doubtful, but agreed to ask a mutual friend Haakon Chevalier to suggest this to Oppenheimer. Chevalier reported back that Oppenheimer was not interested, but when the fact of the approach was revealed by Oppenheimer in 1946, Eltenton was interviewed by the FBI.
Sources: en.wikipedia.org
Didymin (also known as isosakuranetin 7-O-rutinoside or neoponcirin) is an O-methylated flavanone glycoside occurring naturally in citrus fruits, consisting of the flavanone isosakuranetin linked to the disaccharide rutinose.
A soft coup, sometimes referred to as a silent coup or a bloodless coup, is an illegal overthrow of a government that – unlike a regular coup d'état – is achieved without the use of force or violence.
=== Discontinued === 2-BUMP – monoamine oxidase B (MAO-B) inhibitor [238] A-77636 – dopamine D1 receptor agonist [239] Acamprosate/baclofen (PXT-864) – combination of acamprosate (various actions) and baclofen (GABAB receptor agonist) [240] Adrogolide (ABT-431; DAS-431; A-86929 O,O′-diacetate) – dopamine D1 receptor agonist (prodrug of A-86929) [241] AP-001 – various actions [242] Apomorphine inhalation (VR-004; VR-040; VR-400) – non-selective dopamine receptor agonist and other actions [243] Apomorphine intranasal – non-selective dopamine receptor agonist and other actions [244] Apomorphine subcutaneous (ND-0701) – non-selective dopamine receptor agonist and other actions [245] Apomorphine transdermal patch – non-selective dopamine receptor agonist and other actions [246] Arimoclomol (BRX-345; Miplyffa; OR-01; OR-04) – undefined mechanism of action [247] Arundic acid (Arocyte Injection; Cereact Capsule; MK-0724; ONO-2506; Proglia) – various actions [248] Atomoxetine (LY-139603; Strattera; Tomoxetine) – norepinephrine reuptake inhibitor (NRI) [249] AVE-8112 (AVE8112; AVE-8112A) – phosphodiesterase PDE4 inhibitor [250] AX-201 (AX201) – nerve growth factor (NGF) stimulant [251] Bifeprunox (DU-127090) – serotonin 5-HT1A receptor agonist and dopamine D2 receptor agonist [252] BP-897 – dopamine D3 receptor agonist [253] Carbidopa/levodopa (AP-09004; AP-CD/LD) – combination of carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) and levodopa (dopamine precursor) [254] CEP-1347 (KT-7515) – mitogen-activated protein kinase inhibitor and mixed-lineage kinase inhibitor [255] CERE-120 (AAV-NRTN; AAV-NTN; AAV2-neurturin; AAV2-NTN; neurturin gene therapy) – gene therapy, nerve tissue protein modulator, and neurturin agonist [256] Cinpanemab (BIIB-054) – monoclonal antibody against α-synuclein [257] CVXL-0107 – glutamate release inhibitor [258] Dactolisib (BEZ-235; NVP-BEZ-235; NVP-BEZ235-ANA; NVP-BEZ235-NX; RTB-101) – 1-phosphatidylinositol 3 kinase inhibitor and mTOR inhibitor [259] Davunetide intranasal (AL-108; NAP; NAPVSIPQ) – various actions [260] Dihydrexidine (DAR-0100) – dopamine D1 receptor agonist [261] Dihydrexidine (IP-202) – dopamine D1 and D5 receptor agonist [262] DNS-7801 – undefined mechanism of action [263] Embryonic neural cell therapy-Parkinson's Disease - CellFactors (Parkinson's disease cell therapy) – dopaminergic cell replacement [264] Emlenoflast (inzomelid; IZD-174; MCC-7840) – NLR family pyrin domain containing 3 (NLRP3) inhibitor [265] Entacapone (Comtan; Comtess; OR-611) – catechol O-methyltransferase (COMT) inhibitor [266] Ethyl eicosapentaenoic acid (AMR-101; Ethyl-EPA; LAX-101; Miraxion; Vascepa; Vazkepa) – various actions [267] Etrabamine (14-839JL; JL-14839) – dopamine D2 receptor agonist [268] Ezaladcigene resoparvovec (AAV-AADC; AV-201; GZ-404477; NBIb-1817) – gene transference and aromatic-L-amino-acid decarboxylase (AAAD) replacement [269] Fipamezole (BVF-025; JP-1730) – α2-adrenergic receptor antagonist [270] Florbenazine F18 (18F-DTBZ; 18F-AV-133; 18F-FP-dihydrotatetrabenazine; AV-133) – vesticular monoamine transporter 2 (VMAT2) inhibitor and radiopharmaceutical – diagnosis [271] Foliglurax (PXT-2331; PXT002331) – metabotropic glutamate mGlu4 receptor positive allosteric modulator [272] FRM-0334 (EVP-0334) – class I and class II histone deacetylase inhibitor [273] GYKI-52895 – dopamine reuptake inhibitor (DRI) [274] Levetiracetam (Keppra; L-059; SIB-S1; UCB-059; UCB-22059; UCB-L059) – synaptic vesicle glycoprotein 2A (SV2A) modulator [275] Lu-AA47070 (LU-AA-47070) – adenosine A2A receptor antagonist [276] Methylthioninium chloride (MTC; methylene blue; TRx-0014; TRx-014) – various actions [277] Naxagolide (L-647339) – dopamine D2 and D3 receptor agonist [278] Nebicapone (BIA-3202) – catechol O-methyltransferase (COMT) inhibitor [279] Nitecapone (OR-462) – catechol O-methyltransferase (COMT) inhibitor Nitisinone (NTBC; Orfadin; SC-0735; SYN-118) – 4-hydroxyphenylpyruvate dioxygenase inhibitor and dopamine release stimulant [280] NPT-088 (NPT088) – immunoglobulin fusion general amyloid interaction motif (GAIM) based dimer [281] NPT-189 (NPT189) – immunoglobulin fusion protein [282] NW-1048 – monoamine oxidase B (MAO-B) inhibitor [283] NYX-458 – ionotropic glutamate NMDA receptor positive allosteric modulator [284] ODM-103 – catechol O-methyltransferase (COMT) inhibitor [285] Omigapil (CGP-3466; SNT-317; TCH-346) – glyceraldehyde 3 phosphate dehydrogenase (GAPDH) inhibitor [286] OPM-201 (S-221237) – leucine-rich repeat kinase 2 (LRRK2) inhibitor [287] OSU-6162 (OSU6162; PNU-9639; PNU-96391; PNU-96391A) – serotonin 5-HT2A receptor partial agonist (non-hallucinogenic), dopamine D2 receptor partial agonist, and sigma σ1 receptor ligand (so-called "monoaminergic stabilizer") [288] Paliroden (SR-57667; SR-57667B) – nerve growth factor (NGF) stimulant [289] Pardoprunox (SLV-308; SME-308) – dopamine D2 and D3 receptor partial agonist, serotonin 5-HT1A receptor full agonist, and other actions [290] Parkinson's disease gene therapy - Oxford BioMedica (AXO Lenti PD; OXB-101; OXB-102; ProSavin) – gene transference [291] Pegipanermin (DN-TNF; INB-03; LIVNate™; Quellor™; soluble tumour necrosis factor inhibitor; XENP1595; XENP345; XPro 1595; XPro595; XProTM) – tumour necrosis factor alpha (TNFα) inhibitor and immunostimulant [292] PF-06412562 (CVL-562) – dopamine D1 and D5 receptor partial agonist [293] Piclozotan (SUN-4057; SUN-N-4057) – serotonin 5-HT1A receptor agonist – dyskinesia in Parkinson's disease [294] Preclamol ((–)-3-PPP) – dopamine D2 receptor partial agonist [295] Preladenant (MK-3814; privadenant; SCH-420814) – adenosine A2A receptor antagonist [296] Proxison – synthetic flavonoid-based antioxidant [297] Quinelorane (LY-163502) – dopamine D2 receptor agonist [298] Raseglurant (ADX-10059) – metabotropic glutamate mGlu5 receptor negative allosteric modulator [299] Razpipadon (CVL-871; PF-6669571; PF-06669571; PW-0464) – dopamine D1 receptor agonist [300] Renzapride (ATL-1251; AZM-112; BRL-24924) – serotonin 5-HT3 receptor antagonist and serotonin 5-HT4 receptor agonist [301] Research programme: Alzheimer's and Parkinson's disease diagnostic agents - Bayer HealthCare Pharmaceuticals/TauRx – undefined mechanism of action – diagnosis [302] Research programme: AMC therapeutics - Animuscure – undefined mechanism of action [303] Research programme: Ig fusion GAIM dimers - Proclara Biosciences (NPT-288; NPT-007; NPT-014; NPT-289) – various actions [304] Research programme: Parkinson's disease therapeutics - Araclon Biotech (AB-03) – undefined mechanism of action [305] Research programme: Parkinson's disease therapies - Neose/Neuronyx – undefined mechanism of action [306] Research programme: Parkinson's disease therapies - Proteome Systems (EUK-418) – free radical scavenger and oxygen radical scavenger [307] Research programme: Parkinson's disease therapeutics - TauRx Therapeutics (G2 PD; TRx 018) – synuclein inhibitor [308] Research programme: protein aggregation inhibitors - Proclara Biosciences (NPT-001; NPT-002) – various actions [309] Riluzole (PK-26124; Rilutek; RP-54274) – various actions [310] Ropinirole implant – dopamine D2, D3, and D4 receptor agonist [311] Sarsasapogenin (Cogane; JNX-1001; PYM-50028; Smilagenin) – various actions [312] Sipagladenant (KW-6356) – adenosine A2A receptor antagonist [313] SPD-474 – undefined mechanism of action [314] Sumanirole (PNU-95666; U-95666) – dopamine D2 receptor agonist [315] TAK-065 – undefined mechanism of action [316] TAK-071 – muscarinic acetylcholine M1 receptor positive allosteric modulator [317] Tc 99m TRODAT-1 – single-photon emission-computed tomography (SPECT) enhancer – diagnosis [318] Terguride (Dironyl; Mysalfon; SH-406; Teluron; transdihydrolisuride; VUFB-6638; ZK-31224) – dopamine D2 receptor agonist and other actions [319] Tozadenant (A2a-(3); RO4494351; SYN-115) – adenosine A2A receptor antagonist [320] Utreloxastat (EPI-857; PTC-857) – 15-lipoxygenase (15-LOX/ALOX15) inhibitor [321] Vipadenant (BG-14; BIIB-014; BIIB14; CEB-4520; V-2006; VER-11135; VER-A00-11; VER-A00049; VER-ADO-49; VR-2006) – adenosine A2A receptor antagonist [322] [323]
=== Other methods === A commercial source for the cyanide group is diethylaluminum cyanide Et2AlCN which can be prepared from triethylaluminium and HCN. It has been used in nucleophilic addition to ketones. For an example of its use see: Kuwajima Taxol total synthesis Cyanide ions facilitate the coupling of dibromides. Reaction of α,α′-dibromoadipic acid with sodium cyanide in ethanol yields the cyano cyclobutane: Aromatic nitriles can be prepared from base hydrolysis of trichloromethyl aryl ketimines (RC(CCl3)=NH) in the Houben-Fischer synthesis α-Amino acids form nitriles and carbon dioxide via various means of oxidative decarboxylation. Henry Drysdale Dakin discovered this oxidation in 1916. From aryl carboxylic acids (Letts nitrile synthesis) Carbocyanation enables addition of a nitrile group across a multiple bond to yield a further nitrile. Aryl nitriles can be added to alkynes under catalysis by bis(cyclooctadiene)nickel(0) and trimethylphosphine, affording α,β-unsaturated nitriles. Modification of the reaction conditions, for example by employing a different phosphane or adding a frustrated Lewis pair such as trimethylaluminum or triphenylborane, allows addition of non-aromatic nitriles, both saturated and α,β-unsaturated. Carbocyanation reactions that couple two molecules while introducing a nitrile group are also known, using hexabutyldistannane and tosyl cyanide as the cyanide source. Carboxylic acids can be converted to the corresponding nitriles by reaction with indium(III) chloride in acetonitrile at 200 °C.
=== Indian Ocean Forum on Maritime Crime (IOFMC) === The IOFMC enables regional cooperation to form operational responses to maritime crime. This has been implemented as part of the GMCP IO reaction to encourage regional responses. This has enabled the formation of the ‘Prosecutors’ Network’, which allows prosecutors from the different coastal states to coordinate their legal strategies. Legislative reform is consequently possible, and legislation on maritime crime can be created. From this, organisations such as the Southern Route Partnership can be developed.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.